First In Human Study of CX-801 in Advanced Solid Tumors

Part of paid clinical trials in Englewood, Colorado.

Sponsor
CytomX Therapeutics
Study ID
NCT06462794
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumor, Adult

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CX-801 — DRUG
    Investigational drug
  • pembrolizumab — DRUG
    Standard of Care Therapy

Study Details

The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.

Key Dates

Start date
Aug 28, 2024
Status verified
May 2026
Primary completion
Feb 28, 2028
Completion
Jun 30, 2029

Study Design

Enrollment
121 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: CX-801
  • Experimental: CX-801 + pembrolizumab

Primary Outcome Measure

Safety and tolerability of CX-801 as monotherapy and combination therapy [ Time Frame: 44 months ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
The Melanoma and Skin Cancer InstituteEnglewoodColorado80113-
University of Pittsburgh Hillman Cancer CenterPittsburghPennsylvania15232-
SCRI Oncology PartnersNashvilleTennessee37203-

Find similar trials in Englewood, CO

By research site
The Melanoma and Skin Cancer Institute· Englewood, COUniversity of Pittsburgh Hillman Cancer Center· Pittsburgh, PASCRI Oncology Partners· Nashville, TN

Related Studies